Filing Analysis
Lyell Immunopharma issued a press release regarding positive initial clinical data from its Phase 1-2 trial of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product, presented at the ASH Annual Meeting.
📋 Key Facts
- Clinical data pertains to IMPT-314 in patients with large B-cell lymphoma.
- IMPT-314 is a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate.
- The trial aims to increase complete response rates and prolong response duration compared to current approved therapies.
- Data was presented at the 66th American Society of Hematology (ASH) Annual Meeting.
Lyell Immunopharma announced the resignation of Hans Bishop from the Board of Directors and the Nominating and Corporate Governance Committee, effective November 22, 2024.
📋 Key Facts
- Hans Bishop resigned as a member of the Board of Directors on November 22, 2024.
- Mr. Bishop also resigned from the Nominating and Corporate Governance Committee.
- The company explicitly stated that the resignation was not due to any disagreement or dispute with the Company.
Lyell Immunopharma, Inc. filed an 8-K to announce its financial results for the quarterly period ended September 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting period: Quarter ended September 30, 2024.
- Filing date: November 7, 2024.
Lyell Immunopharma completed its acquisition of ImmPACT Bio USA Inc. on October 31, 2024. The transaction includes a combination of cash and equity, along with contingent consideration tied to clinical and regulatory milestones.
🚩 Red Flags
- Significant dilution potential due to 37.5 million shares issued plus up to 12.5 million contingent shares.
- Registration Rights Agreement entered into, allowing sellers to file shelf registration statements for resale of LYEL stock.
📋 Key Facts
- Acquisition closed on October 31, 2024.
- Upfront payment consisted of $30.0 million in cash (adjusted by ~$12.0 million for ImmPACT's existing cash) and 37.5 million shares of LYEL common stock.
- Contingent consideration includes up to 12,500,000 additional shares of LYEL upon clinical or regulatory milestones.
- Includes a low single-digit royalty on future net sales of the dual-targeting CD19/20 CAR T-cell product in the US.
- Dr. Sumant Ramachandra (former CEO of ImmPACT) appointed to Lyell's Board as a Class III independent director.
Lyell Immunopharma has entered into a definitive agreement to acquire ImmPACT Bio USA Inc. via merger. The transaction involves an upfront payment of $30 million in cash and 37.5 million shares of common stock, plus contingent consideration based on clinical/regulatory milestones.
🚩 Red Flags
- Significant dilution: Issuance of 37.5M shares plus up to 12.5M contingent shares represents substantial equity issuance.
- Pipeline discontinuation: Lyell is discontinuing development of LYL797, LYL845, and several TIL/rejuvenation programs to focus resources.
📋 Key Facts
- Acquisition of ImmPACT Bio USA Inc. via a merger with Inspire Merger Sub Inc.
- Upfront consideration: $30,000,000 cash (subject to adjustment for ~$16M estimated cash balance) and 37,500,000 shares of Lyell common stock.
- Contingent consideration: Up to 12,500,000 additional shares of common stock based on clinical or regulatory milestones.
- Royalty component: Low single-digit royalty on future net sales of the dual-targeting CD19/20 CAR T-cell product in the US.
- ImmPACT stockholders have already approved the merger as of the signing date.
- Lyell will appoint an ImmPACT designee to its board as a Class III director.
Lyell Immunopharma, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Report date: August 7, 2024.
- Reporting period: Quarter ended June 30, 2024.
Lyell Immunopharma reported initial clinical and translational data from its Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell product. The data showed dose-dependent efficacy in patients with advanced solid tumors, specifically TNBC and non-small cell lung cancer.
🚩 Red Flags
- One reported Grade 5 respiratory failure event.
- Significant incidence of pneumonitis (22% overall; 17% Grade ≥ 3) specifically noted in patients with lung metastases.
📋 Key Facts
- Phase 1 trial evaluated LYL797 (ROR1-targeted CAR T-cell) in 20 treated patients (16 TNBC, 4 NSCLC).
- Patients had highly pre-treated metastatic disease with a mean of six prior lines of therapy.
- At the 150 x 10^6 dose level, TNBC patients showed an Objective Response Rate (ORR) of 40% and Clinical Benefit Rate (CBR) of 60%.
- Overall CBR across all evaluable dose levels was 38%.
- Safety data: Most frequent Grade 1/2 adverse event was cytokine release syndrome (61%); most frequent Grade ≥ 3 events were pneumonitis (17%) and hypoxia (11%).
- One instance of Grade 5 respiratory failure reported on Day 41.
- No reports of ICANS attributed to LYL797.
- Translational data showed CAR T-cell expansion, infiltration, and persistence in solid tumors for all evaluable biopsies (n=9).
Lyell Immunopharma held its 2024 annual meeting of stockholders on June 14, 2024. The filing reports the results of shareholder votes regarding director elections, auditor ratification, and executive compensation.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- The Annual Meeting was held virtually on June 14, 2024.
- Quorum was established with 198,815,570 shares present (77.98% of outstanding shares).
- Elizabeth Nabel, M.D. and Lynn Seely, M.D. were elected to the Class III Board of Directors until the 2027 annual meeting.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2024.
- Shareholders approved executive compensation on an advisory basis (Say-on-Pay).
- The record date for the meeting was April 16, 2024.
Lyell Immunopharma, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting period: Quarter ended March 31, 2024.
- Filing date: May 6, 2024.
Lyell Immunopharma, Inc. filed an 8-K to announce its financial results for the quarter and full year ended December 31, 2023.
📋 Key Facts
- Reporting period: Quarter and Full Year ended December 31, 2023.
- Filing date: February 28, 2024.
- The filing includes a press release (Exhibit 99.1) containing the financial results.